EAM
IMVT icon

EFG Asset Management’s Immunovant IMVT Stock Holding History

EFG Asset Management’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-130,356
Closed -$2.23M – 177
2025
Q1 		$2.23M Buy
130,356
+56,375
+76% +$1.18M 0.37% 118
2024
Q4 		$1.83M Buy
73,981
+163
+0.2% +$4.62K 0.25% 161
2024
Q3 		$2.1M Buy
73,818
+15,748
+27% +$464K 0.35% 125
2024
Q2 		$1.53M Buy
58,070
+11,000
+23% +$313K 0.27% 148
2024
Q1 		$1.52M Buy
47,070
+20,065
+74% +$732K 0.26% 154
2023
Q4 		$1.14M Buy
+27,005
New +$994K 0.22% 166

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return

EFG Asset Management's IMVT Position: Q2 2025 in Review

EFG Asset Management sold out of Immunovant (IMVT) in Q2 2025, closing a stake of 130,356 shares — an estimated $2.23M sold.

EFG Asset Management first reported a position in IMVT in Q4 2023 and held it in 6 quarters. The position peaked at $2.23M in Q1 2025. 168 funds tracked by Wall St. Rank hold IMVT as of Q2 2025.

  • EFG Asset Management reported no remaining Immunovant position as of Q2 2025 after selling out during the quarter.
  • EFG Asset Management sold 130,356 Immunovant shares in Q2 2025, an estimated $2.23M.
  • EFG Asset Management first reported a position in Immunovant in Q4 2023 and held it in 6 quarters.
  • EFG Asset Management's Immunovant position peaked at $2.23M in Q1 2025.
  • 168 funds tracked by Wall St. Rank held Immunovant as of Q2 2025.

Based on EFG Asset Management's 13F filing for Q2 2025, filed 6 Aug 2025.